Dr. Richard Soll is joining Pepticom’s SAB

We are very excited to announce Dr. Soll joining Pepticom’s Scientific Advisory Board.Presently Senior Advisor, Strategic Initiatives at WuXi AppTec and Head of the WuXi office in Boston, Massachusetts, Dr. Soll’s contributions have led to the discovery of the HCV NS5A inhibitor in the Merck-WuXi partnership, the JAK2 inhibitor Fedratinib at TargeGen (partnered with Celgene/BMS), […]